Plaque

CNEC Global Leap Program Debuts in Barcelona, Highlighting Seven Tech Leaps to Accelerate Intelligence

Retrieved on: 
Wednesday, February 28, 2024

Through technical communities like CNEC, Huawei Cloud aims to connect businesses with the latest global technologies, best practices, and industry trends.

Key Points: 
  • Through technical communities like CNEC, Huawei Cloud aims to connect businesses with the latest global technologies, best practices, and industry trends.
  • Looking ahead to 2024, CNEC will prioritize the strategic integration of cloud native and AI technologies, an effort to accelerate the global adoption and advancement of AI.
  • During the event, CNEC unveiled its Global Leap Program themed "Leap with Cloud Native x AI", which will facilitate extensive technical exchanges, in-depth discussions, and pilot practice showcases.
  • Furthermore, Huawei Cloud held a plaque presentation ceremony to establish the CNEC European Branch to better serve local organizations.

CNEC Global Leap Program Debuts in Barcelona, Highlighting Seven Tech Leaps to Accelerate Intelligence

Retrieved on: 
Wednesday, February 28, 2024

"CNCF boasts numerous projects utilized by leading AI companies like OpenAI, providing the essential technological infrastructure for generative AI," Dolezal stated.

Key Points: 
  • "CNCF boasts numerous projects utilized by leading AI companies like OpenAI, providing the essential technological infrastructure for generative AI," Dolezal stated.
  • Through technical communities like CNEC, Huawei Cloud aims to connect businesses with the latest global technologies, best practices, and industry trends.
  • Looking ahead to 2024, CNEC will prioritize the strategic integration of cloud native and AI technologies, an effort to accelerate the global adoption and advancement of AI.
  • During the event, CNEC unveiled its Global Leap Program themed "Leap with Cloud Native x AI", which will facilitate extensive technical exchanges, in-depth discussions, and pilot practice showcases.

The 50 Most Beautiful College Quads in America

Retrieved on: 
Tuesday, February 27, 2024

College Rank conducted in-depth research to find the 50 most beautiful quads in America.

Key Points: 
  • College Rank conducted in-depth research to find the 50 most beautiful quads in America.
  • Several impressive buildings, including Johnson Chapel and Converse Hall, surround the main quad at Amherst College.
  • Check out the 50 most beautiful quads in America for a full description of these beautiful examples of an American tradition.
  • Then check out the College Rank podcast and College Rank's Instagram .

Vinitaly International Academy Verona 2024: Berlucchi winery announces wine ambassador scholarship

Retrieved on: 
Monday, February 26, 2024

VERONA, Italy, Feb. 26, 2024 /PRNewswire-PRWeb/ -- In April, Verona will host over 60 international wine professionals engaging in a comprehensive program encompassing five days of tastings, masterclasses, and seminars that compose the Vinitaly International Academy Italian Wine Ambassador Certification course. Nine distinguished wine consortiums and associations will contribute as official supporters of the program, while Berlucchi winery will return this year as an official educational supporter. Berlucchi's commitment this year includes the funding of a scholarship awarded to the most deserving candidate.

Key Points: 
  • The Vinitaly International Academy hosts the prestigious Italian Wine Ambassadors course in Verona from 4-8 April 2024.
  • VERONA, Italy, Feb. 26, 2024 /PRNewswire-PRWeb/ -- In April, Verona will host over 60 international wine professionals engaging in a comprehensive program encompassing five days of tastings, masterclasses, and seminars that compose the Vinitaly International Academy Italian Wine Ambassador Certification course.
  • Nine distinguished wine consortiums and associations will contribute as official supporters of the program, while Berlucchi winery will return this year as an official educational supporter.
  • This is why every Vinitaly International Academy project, with which we have been collaborating for some time, represents a real opportunity that we welcome with joy.

Healthy Foods Deliver Defense Against Cancer and Heart Disease

Retrieved on: 
Wednesday, February 21, 2024

The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.

Key Points: 
  • The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.
  • According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States, followed by cancer.
  • There are a number of factors that can increase the risk of developing heart disease, including high blood pressure, high cholesterol, obesity and diabetes .
  • Research shows that in addition to inhibiting colon, prostate and breast cancer cell growth, they can also protect against heart disease.

The College for Financial Planning®—a Kaplan Company Releases 2024 Survey of Financial Planning Professionals’ Views on Issues Ranging from Job Satisfaction to DEI to AI

Retrieved on: 
Monday, February 12, 2024

The College for Financial Planning—a Kaplan Company has released its 2024 Survey of Trends , which explores the diverse experiences, interests, and viewpoints of professionals in the financial services industry*.

Key Points: 
  • The College for Financial Planning—a Kaplan Company has released its 2024 Survey of Trends , which explores the diverse experiences, interests, and viewpoints of professionals in the financial services industry*.
  • Those who believe the industry is doing too little say it is mainly because they still see a lack of representation within the industry.
  • "The College for Financial Planning is committed to providing professionals with the most up-to-date insights and knowledge and supporting their career growth at every stage.
  • From June through August 2023, 951 respondents completed the survey, although not all of them answered every question.

Jaya Biosciences Presents Promising Preclinical Data in Alzheimer’s Disease at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Monday, February 12, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies to address unmet needs in genetically defined neurodegeneration, reported non-clinical data at the 20th Annual WORLDSymposium™, a leading research conference on lysosomal diseases. During a late-breaking news platform presentation, Jaya Biosciences’ scientific founder, Prof. Mark Sands, reported preliminary human genetic analysis suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s patients, as well as preclinical efficacy results in the animal model of Alzheimer’s disease (AD) for JB111, the Company’s lead therapy.

Key Points: 
  • “We are thrilled to showcase a new paradigm for the treatment of genetically defined neurodegeneration at the 20th WORLDSymposium™,” said Pawel Krysiak, President and CEO of JayaBio.
  • “The preclinical data we presented demonstrate a tremendous promise of targeting PPT1 haploinsufficiency in Alzheimer’s disease.
  • Heterozygosity of five different lysosomal enzyme genes (PPT1, NAGLU, GALC, IDUA, GUSB) significantly affects amyloid precursor protein (APP) processing and favors pro-amyloidogenic pathway.
  • CNS-directed, AAV-mediated gene therapy significantly increases the life span and improves cognitive function of 5xFAD/PPT1+/- mice.

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

Retrieved on: 
Thursday, February 8, 2024

These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.

Key Points: 
  • These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.
  • In all multicenter and single clinical studies performed to date, Cleerly’s products have consistently demonstrated robust clinical utility, including higher diagnostic accuracy and stronger prognostic risk stratification over such historical tests as nuclear SPECT stress testing and FFRCT2-7.
  • Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.
  • Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

Little Dogs Have Smaller Teeth, But Bigger Teeth Problems

Retrieved on: 
Wednesday, February 7, 2024

AUSTIN, Texas, Feb. 7, 2024 /PRNewswire/ -- National Pet Dental Health Month is underway and Thrive Pet Healthcare, a leading veterinary healthcare network with more than 380 locations in 37 states across the U.S., is spotlighting a concerning trend – small dogs tend to develop dental problems more rapidly and at younger ages than bigger dogs.

Key Points: 
  • Small dogs tend to develop dental problems more rapidly and at younger ages than bigger dogs.
  • "Their compact mouths, heads and faces, along with other genetic features, predispose them to rapid tartar buildup, plaque and gingivitis more than larger dogs."
  • Brachycephalic or flat-faced dog breeds like Boston terriers and pugs often experience crowded or misaligned teeth, leading to early onset periodontal disease.
  • No matter a dog's size, signs of dental problems may not be obvious to their owner.

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Retrieved on: 
Thursday, February 1, 2024

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.
  • Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models.
  • In line with IGC Pharma's artificial intelligence and machine learning ("AI/ML") initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63's toxicology and protein interactions.
  • The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in our Alzheimer's mouse model, reinforcing its potential as a promising treatment.